Brief: Valbiotis Receives US And European TOTUM-070 Patent For Reducing Hypercholesterolemia

Valbiotis SA

14/09/2020 16:41

Sept 14 (Reuters) - Valbiotis SA  ALVAL.PA :
    * VALBIOTIS RECEIVES US AND EUROPEAN TOTUM-070 PATENT FOR REDUCING HYPERCHOLESTEROLEMIA
    * TOTUM-070 EXCLUSIVITY GUARANTEED IN UNITED STATES AND IN EUROPE FOR REDUCING BLOOD
LDL-CHOLESTEROL LEVELS, A CARDIOVASCULAR DISEASE RISK FACTOR
    * INTELLECTUAL PROPERTY RIGHTS PROTECTING COMPOSITION OF TOTUM-070 ACTIVE SUBSTANCE FOR FOOD
AND
PHARMACEUTICAL APPLICATIONS
    * A MILESTONE IN FURTHER DEVELOPMENT OF TOTUM-070, IN SEARCH FOR COMMERCIAL PARTNERSHIPS AND
IN
RECEIVING APPROVAL FOR HEALTH CLAIMS IN EUROPE AND NORTH AMERICA.

Source text for Eikon:  ID:nBw22slF7a 
Further company coverage:  ALVAL.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))